Drug Name Aricept

Rimonabant (also known as SR141716; trade names Acomplia, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, Zimulti, and Riomont) is an anorectic antiobesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main effect is reduction in appetite. Rimonabant was the first selective CB1 receptor blocker to be approved for use anywhere in the world.
The bottom line is that if you use an HbA1c measurement as a screening test, you'll have a lot of false-negatives and some false-positives," said Mary Rhee, MD, Assistant Professor of Endocrinology at Emory University in Atlanta. And in this day and age when diabetes is a worsening public health epidemic not only in the U.S. but also around the world, we can't afford to end up with more cases of undiagnosed diabetes."

 

Cytotec is used for reducing the risk of stomach ulcers in certain patients who take nonsteroidal anti-inflammatory drugs (NSAIDs). It may also be used for other conditions as determined by your doctor.
On 23 October 2008, the European Medicines Agency (EMEA) issued a press release stating its Committee for Medical Products for Human Use (CHMP) had concluded the benefits of Acomplia no longer outweighed its risks, and subsequently recommended the product be suspended from the UK market. Sanofi-Aventis later released a press statement stating the drug had been suspended. Approval of the drug was officially withdrawn by the EMEA on 16 January 2009.